Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients

Published:2012-05-29 Issue:1 Volume:107 Page:37-42
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Lorusso D,Scambia G,Amadio G,di Legge A,Pietragalla A,De Vincenzo R,Masciullo V,Di Stefano M,Mangili G,Citterio G,Mantori M,Lambiase A,Bordignon C

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2012233.pdf

Reference30 articles.

1. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, Mutch DG, Burger RA, Swart AM, Trimble EL, Accario-Winslow C, Roth LM (2009) Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27: 1419–1425

2. Calcinotto A, Grioni M, Jachetti E, Curnis F, Mondino A, Parmiani G, Corti A, Bellone M (2012) Targeting TNF-a to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy. J Immunol 188: 2687–2694

3. Cannistra SA (2004) Cancer of the ovary. N Engl J Med 35: 2519–2529

4. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumours. Proc Natl Acad Sci 72: 3666–3670

5. Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A (2000) Enhancement of tumour necrosis factor alpha antitumour immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 18: 1185–1190

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer-specific glycosylation of CD13 impacts its detection and activity in preclinical cancer tissues;iScience;2023-11

2. Peptide-Drug Conjugates: A New Hope for Cancer Management;Molecules;2022-10-25

3. Targeting the Blood–Brain Tumor Barrier with Tumor Necrosis Factor-α;Pharmaceutics;2022-07-06

4. Synthesis of 68Ga-Labeled cNGR-Based Glycopeptides and In Vivo Evaluation by PET Imaging;Pharmaceutics;2021-12-07

5. Is tumour-expressed aminopeptidase N (APN/CD13) structurally and functionally unique?;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2021-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3